The association of COMT genotype with buproprion treatment response in the treatment of major depressive disorder
Brain and Behavior2020Vol. 10(7), pp. e01692–e01692
Citations Over Time
Abstract
High-dose bupropion is beneficial for MDD patients with Met/Val or Val/Val COMT genotypes, but not for patients with Met/Met genotype. Prospective studies are necessary to replicate this pharmacodynamic relationship between bupropion and COMT genotypes and explore economic and clinical outcomes.
Related Papers
- → Pharmacokinetics of Single‐ and Multiple‐Dose Bupropion in Elderly Patients with Depression(1995)73 cited
- → Acute psychosis following sustained release bupropion overdose(2004)21 cited
- [Successful treatment of depression in a Parkinson disease patient with bupropion].(2000)
- Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type.(1983)
- → The Many Uses of Bupropion and Bupropion Sustained Release (SR) in Adults(2002)15 cited